10 October 2026
: Case report
Case Report: Botulinum Toxin Type A Injection for Bruxism Following Left Basal Ganglia Hemorrhage
Unusual or unexpected effect of treatment
Jialing Wang ABEF 1, Xudong Zhu CFG 2, Yanjie Fu ACD 1, Ya Zheng ACD 1*DOI: 10.12659/AJCR.953163
Am J Case Rep 2026; 27:e953163
Abstract
BACKGROUND: Post‑stroke bruxism is an underrecognized complication that may impair oral function, cause orofacial pain, and negatively impact rehabilitation outcomes. Botulinum toxin type A (BoNT‑A) has been reported for bruxism, but its application in post‑stroke populations remains sparsely documented. This case describes the assessment and treatment of bruxism following cerebral hemorrhage, utilizing the Standardized Tool for the Assessment of Bruxism (STAB) as a structured multidimensional framework.
CASE REPORT: A 40-year-old man developed bruxism during recovery from a massive left hemispheric intracerebral hemorrhage after decompressive craniectomy and hematoma evacuation. About 3 months after admission, he began to exhibit bilateral masseter muscle hypertrophy with marked tenderness, temporomandibular joint pain, and drooling from the right mouth corner, with no prior history of bruxism. STAB-based evaluation yielded the following Axis A findings: Subject-based assessment revealed nocturnal grinding reported by caregivers. Clinically based assessment revealed bilateral masseter hypertrophy, tenderness on palpation, and dental wear. Instrument-based assessment (surface electromyography used for injection guidance) confirmed increased masseter muscle activity at rest and during clenching. Symptoms were refractory to occlusal splint therapy combined with hot compresses. At 48 hours after electromyography-guided injection into the bilateral masseter muscles (50 U per side, divided into 3 sites per side), muscle tension and tenderness were markedly reduced, and clinical improvement persisted at 6-month follow-up.
CONCLUSIONS: In this single case, BoNT‑A injection was temporally associated with symptom relief in post-stroke bruxism. STAB provided a structured multidimensional assessment framework. These descriptive findings have limited generalizability. Controlled studies are needed to establish the efficacy and safety of this intervention in the post‑stroke population.
Keywords: Botulinum Toxins, Type A, bruxism, Cerebral Hemorrhage
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954074
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953592
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954225
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952870
Most Viewed Current Articles
07 Dec 2021 : Case report
28,712,481
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
180,580
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
124,319
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
08 May 2026 : Case report
95,142
DOI :10.12659/AJCR.952158
Am J Case Rep 2026; 27:e952158






